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The human UDP-glucuronosyltransferase 1A1 (UGT1A1), one of the most essential conjugative enzymes,
is responsible for the metabolism and detoxification of bilirubin and other endogenous substances, as
well as many different xenobiotic compounds. Deciphering UGT1A1 relevance to human diseases and
characterizing the effects of small molecules on the activities of UGT1A1 requires reliable tools for
probing the function of this key enzyme in complex biological matrices. Herein, an easy-to-use assay for
highly-selective and sensitive monitoring of UGT1A1 activities in various biological matrices, using liquid
chromatography with fluorescence detection (LC-FD), has been developed and validated. The newly
developed LC-FD based assay has been confirmed in terms of sensitivity, specificity, precision, quanti-
tative linear range and stability. One of its main advantages is lowering the limits of detection and
quantification by about 100-fold in comparison to the previous assay that used the same probe substrate,
enabling reliable quantification of lower amounts of active enzyme than any other method. The precision
test demonstrated that both intra- and inter-day variations for this assay were less than 5.5%. Further-
more, the newly developed assay has also been successfully used to screen and characterize the regu-
latory effects of small molecules on the expression level of UGT1A1 in living cells. Overall, an easy-to-use
LC-FD based assay has been developed for ultra-sensitive UGT1A1 activities measurements in various
biological systems, providing an inexpensive and practical approach for exploring the role of UGT1A1 in
human diseases, interactions with xenobiotics, and characterization modulatory effects of small mole-
cules on this conjugative enzyme.
© 2020 Xi'an Jiaotong University. Production and hosting by Elsevier B.V. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
UDP-glucuronosyltransferases1A1 (UGT1A1) is one of the most
essential enzymes responsible for the biotransformation and
detoxification of the endogenous toxin bilirubin, and metabolicUniversity.
linary Integrative Medicine
Medicine, Shanghai, 201203,
. Wang), geguangbo@dicp.ac.
on and hosting by Elsevier B.V. Thiclearance of a variety of crucial therapeutic drugs and other xeno-
biotics [1,2]. Multiple evidences have indicated that dysfunction or
potent inhibition of hepatic UGT1A1 may result in a disorder of
bilirubin metabolism, causing different degrees of hyper-
bilirubinemia, liver disorders, and other diseases [3,4]. In addition,
reduced expression/activities of UGT1A1 may trigger clinically
relevant drug/herbs-drug interactions by affecting the pharmaco-
kinetic behaviors of the UGT1A1-substrate drugs [5e7]. Due to the
vital roles of UGT1A1 in biotransformation of both endogenous
compounds (particularly bilirubin conjugation) and drugs, the Eu-
ropean Medicines Agency (EMA) and the US Food and Drug
Administration (FDA) have recommended that the inhibitions is an open access article under the CC BY-NC-ND license (http://creativecommons.
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UGT1A1 activities should be tested before marketing approval [8].
A panel of analytical methods have already been reported for
studying the inhibition potency of different drug candidates or
phytochemical products on the human UGT1A1, either employing
the recombinant enzyme or liver preparations, such as microsomes
[9]. However, most of the previously reported methods had
considerable limitations in sensing UGT1A1 activities in biological
samples that vary from instability of the substrate under the assay
conditions, to poor selectivity towards UGT1A1 over other hepatic
UGTs, to low sensitivity unless liquid chromatography-tandem
mass spectrometry (LC-MS/MS) is used as the analytical tool
[10,11]. Usually, the LC-MS/MS based assays are costly and labor-
intensive, because the expensive instruments and skillful opera-
tors are always required.
Recently, we have developed two isoform-specific fluorogenic
substrates for the human UGT1A1, which provide alternative
methods for high-throughput detection of this key enzyme, using
fluorescence-based assays [12,13]. In particular, a recent investi-
gation has clearly demonstrated that N-butyl-4-(4-
hydroxyphenyl)-1,8-naphthalimide (NHPN) is an isoform-specific
fluorogenic probe for UGT1A1 (Fig. 1A), which binds at the bili-
rubin binding site on this key enzyme, is highly suitable for
replacing bilirubin for measuring UGT1A1 activities and investi-
gating UGT1A1-ligand interactions in tissue preparations [13,14].
Nevertheless, even though the specificity of NHPN for UGT1A1 is
high, the fluorogenic properties of this probe are not good enough,
mainly due to short emission wavelength of its O-glucuronide
(<520 nm). This is a problem since some endogenous compounds
and phytochemicals emit fluorescence signals at visible wave-
lengths (400e600 nm), leading to a high background fluorescenceFig. 1. The chemical structure of NHPN and its mechanism for sensing UGT1A1 activity
(A). Liquid chromatography-fluorescence detection (LC-FD) chromatograms of NHPN
and NHPNG (B). (a) NHPN only, (b) NHPN was co-incubated with UDPGA in the
presence of activated HLM (0.5 mg/mL) at 37 C for 20 min, (c) NHPNG only, (d) NHPN
was co-incubated with HLM (0.5 mg/mL) but without UDPGA, (e) buffer only. The
fluorescence signals of NHPN and NHPNG were recorded using excitation wavelength
of 370 nm and emission wavelength of 520 nm.that may strongly affect the detection of NHPN O-glucuronide,
lowering its sensitivity and accuracy. Hence, it is necessary to
develop a practical and accurate method for highly selective and
ultra-sensitive probing of UGT1A1 activities in complex biological
matrix. The practical approach is to take advantage of the high
specificity of NHPN and combine it with improved analytical assays
that include advanced fluorescence detection, allowing taking full
benefits of this newly developed fluorogenic substrate for UGT1A1.
In the present study, a reliable and easy-to-use assay for high
sensitivity and selectivity probing of UGT1A1 activities in various
biological systems is presented in details. To this end, NHPN was
used as the fluorogenic substrate, while liquid chromatography
with fluorescence detection (LC-FD) was used to separate the target
analytes without interference from the endogenous matrix. The
assay was fully validated in terms of sensitivity, specificity, preci-
sion, quantitative linear range and stability. Furthermore, the newly
developed LC-FD based assay was successfully used to measure
UGT1A1 activities in tissue preparations, as well as to screen and
characterize the regulatory effects of small molecules on this con-
jugative enzyme in living cells. Collectively, these findings provided
a practical and reliable assay for probing UGT1A1 activities, which
would strongly facilitate UGT1A1-associated studies in both aca-
demic and industrial fields.
2. Methods and experimental
2.1. Reagents and materials
The fluorogenic probe substrate N-butyl-4-(4-hydroxyphenyl)-
1,8-naphthalimide (NHPN) and its O-glucuronide (NHPNG) were
synthesized and purified (purity98%) according to the previously
reported scheme [13]. Nilotinib and chrysin were from Dalian
Meilun Biotech Co., Ltd. (Meilun, Dalian, China). The tissue prepa-
rations, including pooled human liver microsomes (HLM), pooled
human intestine microsomes (HIM), pooled human kidney micro-
somes (HKM), and pooled human lung microsomes (HLuM) were
purchased from Celsis Inc. (Baltimore, MD, USA). Recombinant
human UGT1A1 was from BD Biosciences (Woburn, MA, USA).
Stably transfected HeLa cells (named HeLa-UGT1A1 cells) were
constructed as previously reported [15e17]. The uridine
diphosphate-glucuronic acid (UDPGA), polyethylene glycol hex-
adecyl ether (Brij 58) and anti-GAPDH antibody (G8795) were
purchased from Sigma-Aldrich (St. Louis, MO, USA). Anti-UGT1A1
antibody (ab194697) was obtained from Abcam (Cambridge, MA).
The reagents for the SimpleWestern blotting system were pur-
chased from ProteinSimple (San Jose, CA). Ultrapure water purified
byMilli-Q® IntegralWater Purification System (Millipore, USA)was
used throughout, while LC grade methanol, acetonitrile, and formic
acid were ordered from Tedia (Fairfield, USA).
2.2. Chromatography and analytical conditions
Both NHPN and NHPNG were analyzed by a UFLC system (Shi-
madzu, Kyoto, Japan), equipped with a CBM-20A communications
bus module, two LC-20AD pumps, a DGU-20A5R vacuum degasser,
a SIL-20AC autosampler, a CTO-20AC column oven, and an RF-20A
fluorescence detector. A Shim-pack VP-ODS C18 column
(4.6 mm  150 mm, 5 mm, Shimadzu) was used in this study, and
the column temperature was maintained at 40 C. The fluorescence
signals of NHPN and NHPNG were recorded with the excitation
wavelength at 370 nm, while the emission wavelength was set at
520 nm [13]. Themobile phasewas amixture of acetonitrile (A) and
0.2% formic acid (B). The following gradient elution program was
used: 0e0.5 min, 40%e20% B; 0.5e1.8 min, 20%e5% B; 1.8e3.8 min,
5% B; 3.8e5 min, 20%e40% B; and 5e6 min, balance to 40% B.
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In this study, the limit of detection (LOD), the limit of quantifi-
cation (LOQ), the linear range for UGT1A1 activities detection,
matrix effects, as well as the precision and stability of the newly
developed LC-FD based assay were carefully investigated. LOD and
LOQ were determined as the fluorescence signals of NHPNG that
produces three and ten folds of the baseline noise, respectively.
Standard curves were constructed by using seven concentrations of
both NHPN and NHPNG. The linearity of the method was evaluated
by linear regression analysis. The inter-day and intra-day precision
of the newly identified LC-FD based method was assessed by
analyzing three different batches of samples and different con-
centrations of NHPN (0.2 mM, 1 mM and 8 mM) and NHPNG (2 nM,
20 nM, 80 nM). To assess intra-day precision, the NHPN and NHPNG
concentrations in each sample were measured within 24 h. For
inter-day assays, NHPN and NHPNG in each sample were quantified
for three consecutive days. The overall precision was expressed
using relative standard deviation (%, RSD). Stability was evaluated
by analyzing the concentrations of NHPNG in UGTs reaction mix-
tures stored for 24 h or 48 h at 4 C.
2.4. Enzymatic activities and kinetic analyses
The activities and kinetic behavior of NHPN-O-glucuronidation
were investigated in both recombinant human UGT1A1 and pooled
HLM. Prior to kinetic analyses, the linear fluorescent responses with
respect to protein concentration and reaction time in each type of
sample were investigated. After that, the kinetic plots of recombi-
nant UGT1A1-mediated NHPN-O-glucuronidation were con-
structed using the following NHPN concentrations 0, 0.1, 0.5, 1, 2,
and 5 mM. The protein concentrations were 0.01 mg/mL for both
recombinant UGT1A1 and HLM. The relationship between the
substrate concentration [S] and the rate of formation NHPNG [V]
was plotted, and the Hill kinetic equation (Eq. 1) was employed to
calculate the kinetic parameters.
V ¼ Vmax S n/(S50n þ S n) (1)
Here, V is the O-glucuronidation rate, Vmax is the maximum O-
glucuronidation rate, S is the NHPN concentration, S50 is the NHPN
concentration resulting in 50% of Vmax, and n is the Hill coefficient.
2.5. Determination of UGT1A1 activities and protein level in
biological samples
The UGT1A1 activities in tissue preparations from different
human samples, including HLM, HIM, HKM and HLuM, were
measured by the newly developed LC-FD assay. Tissue preparations
(0.2 mg/mL, final protein concentration) were first activated by pre-
incubation with Brij 58 on ice for 20 min. Subsequently, a total
volume of 90 mL incubation system consisting of NHPN (5 mM, final
concentration), Tris-HCl buffer (50 mM, pH 7.4), MgCl2 (5 mM), and
the tissue preparation (mixed with Brij 58) was pre-incubated at
37 C for 3 min, and then reaction was initiated by the addition of
UDPGA (dissolved in water) to a final concentration of 4 mM.
Following incubation at 37 C for 30 min, 100 mL ice-cold acetoni-
trile was added to terminate the reaction. Following centrifugation
at 20,000 g for 20 min, the supernatant was subjected to LC-FD
analysis. Meanwhile, the UGT1A1 protein levels in HLM, HIM,
HKM and HLuM could be assayed by the SimpleWestern blotting
system. For the latter, in brief, 3 mL of total protein lysate (0.4 mg/
mL, final concentration) was loaded into a SimpleWes assay plate
(12- to 230-kDa, ProteinSimple, USA) and 400 nL of each sample
was withdrawn through a capillary according to themanufacturer’sinstruction.
2.6. UGT1A1 inhibition assays using various enzyme sources
Nilotinib (a known human UGT1A1 inhibitor) was used for
testing the efficiency of the newly developed LC-FD based assay to
monitor the O-glucuronidation rates of NHPN in UGT1A1 inhibition
assays by various biological systems [18,19]. HLM (0.05mg/mL, final
concentration) was first pre-incubated with the same concentra-
tion of Brij 58 on ice for 20 min and then at 37 C for 3 min.
Thereafter, an incubation system was conducted as described in
Section 2.5 with or without nilotinib (DMSO only). Following in-
cubation for 30 min at 37 C, 100 mL ice-cold acetonitrile was added
to the incubation system to terminate the reaction. Subsequently,
the reaction mixture was centrifuged at 20,000 g for 20 min. The
supernatant was subjected to LC-FD analysis. As for UGT1A1 inhi-
bition assays in living cells, Hela-UGT1A1 cell lines were grown in
DMEM/high glucose medium supplemented with 10% fetal bovine
serum (FBS), in a humidified atmosphere (95% air and 5% CO2) at
37 C. Hela-UGT1A1 cells were seeded in 96-well plates. When cells
in 96-well plates were about 50% confluent, they were treated with
nilotinib for 1 h. After that, cells were treated with NHPN (50 mM,
final concentration) for 3 h, then terminated by adding the equal
volume of ice-cold acetonitrile. The reaction mixture was centri-
fuged at 20,000 g for 20 min. The supernatant was subjected to LC-
FD analysis. The IC50 values of nilotinib on UGT1A1-mediated
NHPN-O-glucuronidation in HLM and in recombinant UGT1A1
were estimated by using GraphPad Prism V6.0 (Graphpad Software
Inc., La Jolla, USA).
2.7. UGT1A1 induction assays in living cells
Chrysin was used as a positive inducer of UGT1A1 [20,21]. Here
we used it to try and induce UGT1A1 in living cells. In brief, Caco-2
cells were cultured in DMEM/high glucose medium, supplemented
with 10% FBS and 1% penicillin-streptomycin solution, in a hu-
midified atmosphere (95% air and 5% CO2) at 37 C. The cells were
seeded in 6-well plates and 96-well plates, respectively. Chrysin
was added into the cell culture system, at the final concentrations
of either 2 mM, 10 mM, or 25 mM. Following 72 h co-incubation with
chrysin, the cells were collected for mRNA assay and UGT1A1 ac-
tivities assay. For mRNA level assay, the cells were collected with
RNAiso Plus reagent and the total RNA was extracted as previously
described [22]. The cDNA was synthesized from total RNA using
RNA PCR kit. Real-time PCR experiments were performed on an ABI
7500 real-time PCR System. The primers used are listed in Table S1
[23,24]. For UGT1A1 activities assay, after the final day of induction
treatment, the cell medium was discarded and the cultured cells
were incubated with 50 mM NHPN in a serum-free medium. After
3 h incubation, 50 mL of the medium in each well was mixed with
ice-cold acetonitrile (50 mL). The mixture was then centrifuged at
20,000 g for 20 min, and the supernatant was subjected to LC-FD
analysis.
3. Results and discussion
3.1. Method development
As mentioned above, we are looking for a way to avoid the
interference of endogenous substances and some tested drugs or
other xenobiotics which may affect the fluorescence output of the
substrate NHPN and its NHPNG [13]. To this end, an LC-FD based
assay was developed via integration of the advantages of both
chromatographic separation and fluorescence detection. As shown
in Fig. 1B, at the excitation wavelength of 370 nm, both NHPN and
Fig. 2. The standard curves of NHPN (A) and NHPNG (B) in Tris-HCl and acetonitrile (1:1, v/v), by using LC-FD based assay. The standard curves of NHPN (C) and NHPNG (D) in Tris-
HCl and acetonitrile (1:1, v/v), by using microplate reader based assay.
Table 1
The linear range, LOD, and LOQ of NHPNG using microplate reader and LC-FD.
Method Analyte Linear (nM) LOD (nM) LOQ (nM)
Microplate reader NHPNG 100e30000 40 100
LC-FD NHPNG 1e100 0.5 1
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separated within 3.0 min. The chromatographic separation using
acetonitrile (A) and 0.2% formic acid-water (B) as the mobile toTable 2
Intra- and inter-day variability of the LC-FD based assay for quantitative determination o
Compound Theoretical concentrations Intra-day (n ¼ 3)
Measured concentratio
NHPN 0.2 mM 0.19 mM
1 mM 1.07 mM
8 mM 7.76 mM
NHPNG 2 nM 2.52 nM
20 nM 19.95 nM
80 nM 81.86 nM
Table 3
Stability of the main product NHPNG in reaction mixtures.
Analyte Enzyme source Conditions Ini
NHPNG HLM 4 C, 24 h 4.5
HLM 4 C, 48 h 4.5
HLM 4 C, 24 h 39.
HLM 4 C, 48 h 39.
HLM 4 C, 24 h 81.
HLM 4 C, 48 h 81.generate the mobile phase and the suitable gradient resulted in
very high resolution and separation of NHPN and NHPNG (Fig. S1).
Notably, most of the endogenous compounds could already be
eluted from the ODS columnwithin the first minute (near the dead
time), which greatly reduced the interference from endogenous
matrix during fluorescence analysis of the two aim analytes (the
retention times of the aim analytes were 2.51 min and 1.53 min, for
NHPN and NHPNG, respectively). The specificity of the newly
developed LC-FD method for detection of NHPN or NHPNG is very
high. By the way, as shown in Fig. S2, no interference peaks weref NHPN and NHPNG.
Inter-day (n ¼ 3)
n RSD (%) Measured concentration RSD (%)
0.71 0.18 mM 3.90
1.96 0.99 mM 5.03
1.12 7.29 mM 5.33
3.69 2.38 nM 1.91
1.10 18.92 nM 4.40
1.74 79.70 nM 1.52
tial conc. (nM) Measured conc. (nM) Recovery (%)
2 4.33 95.79
2 4.35 96.23
92 39.16 98.10
92 38.94 97.54
01 80.19 98,98
01 78.86 97.34
Fig. 3. Enzymatic kinetic plots of NHPN-O-glucuronidation in HLM (A) and in recombinant human UGT1A1 (B).
Fig. 4. NHPN-O-glucuronidation activities (A) and protein levels (B) of UGT1A1 in HLM, HIM, HKM and HLuM.
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NHPNG.3.2. Method validation
The newly developed LC-FD based assay was rigorously vali-
dated in terms of linear range, precision, accuracy and stability. As
depicted in Figs. 2A and B, the calibration curves of both NHPN and
NHPNG exhibited good linearity between peak areas and concen-
trations while using this newly developed LC-FD based assay,
within the linear range of 0.1e20 mM and 2e100 nM, for NHPN and
NHPNG, respectively. Meanwhile, as shown in Figs. 2C and D, the
calibration curves were also constructed for NHPN and NHPNG and
it showed satisfactory linearity between the fluorescence response
and the concentration within the range of 0e25 mM and 0e16 mM,
respectively. The linear fluorescence responses with increasing
concentrations of recombinant hUGT1A1 were also investigated
and are presented in Fig. S3. Notably, the LOQ of NHPNG was
calculated as low as 1 nM (Table 1), which was equivalent to that of
the generated NHPNG in 0.16 mg/mL of hUGT1A1 under optimized
conditions (1 mMNHPNwas incubated with hUGT1A1 for 30 min at
37 C). To the best of our knowledge, the described LC-FD based
method is currently the most sensitive UGT1A1 activities assay. The
intra-day and inter-day variabilities of this assay were also deter-
mined via quantification of the two main analytes in different
samples. As shown in Table 2, the relative standard deviation (RSD)
for quantification of the two analytes was less than 5.5% and 5.0%,for NHPN and NHPNG, respectively. Furthermore, as shown in
Table 3, the stability of NHPNG in different reaction mixtures was
tested by analyzing the samples stored at 4 C for different storage
time (0 h, 24 h and 48 h). The results clearly showed that NHPNG in
the reaction mixture was stable after storage of 48 h, with over 90%
recovery. These findings suggested that the newly developed LC-FD
based assay is highly sensitive and reliable, making it is suitable for
sensing UGT1A1 activities in biological samples.3.3. Kinetic analyses using the LC-FD based assay
Enzymatic kinetic behavior of the maker reaction is an impor-
tant indication for sensing the real activities of the target enzyme in
biological samples [25]. Unfortunately, kinetic plots of NHPN-O-
glucuronidation could hardly be examined by the microplate
reader-based assay, owing to the limited sensitivity at low substrate
concentrations. In the present study, this problem has been solved
and the kinetic plots of NHPN-O-glucuronidation in HLM and in
recombinant hUGT1A1 were carefully analyzed using the newly
developed LC-FD based method. The kinetic curves of NHPN-O-
glucuronidation in both recombinant hUGT1A1 and HLM are dis-
played in Fig. 3. It is clear that the kinetic behaviors of NHPN-O-
glucuronidation in both HLM and UGT1A1 are well-fitted to the Hill
equation, and the derived kinetic constants are listed in Table S2.
Hence, NHPN-O-glucuronidation in both HLM and UGT1A1
exhibited similar kinetic behaviors, with quite similar S50 values
(0.27 mM in recombinant UGT1A1 and 0.41 mM in HLM) and similar
Fig. 5. The dose-inhibition curves of nilotinib against UGT1A1-catalyzed NHPN-O-glucuronidation in various enzyme sources, including recombinant UGT1A1 (A), HLM (B) and
Hela-UGT1A1 living cells (C).
Fig. 6. Induction of UGT1A1 by different doses of chrysin (0 mM, 2 mM, 10 mM, 25 mM) in living Caco-2 cells. (A) The UGT1A1 mRNA levels were monitored by real-time PCR, and (B)
the UGT1A1 activity was determined by the LC-FD based assay.
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and 307.6 pmol/min/mg protein in HLM). These findings clearly
demonstrated that NHPN is a very high-affinity substrate for
UGT1A1, with an S50 value of less than 0.5 mM, which is far below
the S50 value of other UGT1A1 probe substrates, such as etoposide
(S50 ¼ 285 mM in HLM) or NCHN (S50 ¼ 365 mM in HLM) [12,26].3.4. Detection of UGT1A1 activities in tissue preparations
To further explore the practicability of this newly developed LC-
FD based assay for sensing UGT1A1 activities in real samples, this
assay was applied for sensing UGT1A1 activities in real samples. As
shown in Fig. 4A, the UGT1A1 activities in microsomes from HLM,
HIM, HKM and HLuM were determined by the LC-FD, using NHPN
as the probe substrate. In addition, the protein levels of UGT1A1 in
the same tissue preparations were assayed using Western blotting.
The results clearly demonstrated that UGT1A1 was abundant in the
human liver and the small intestine, barely detected in the kidney,
and was undetectable in lung microsomes (Fig. 4B). These findings
were highly consistent with those of several previous reports
regarding UGT1A1 expression in the human body [27] and with the
protein levels of UGT1A1 listed in the protein atlas database
(https://www.proteinatlas.org/). It is worth noting that the deter-
mined UGT1A1 activities in the different tissue preparations are in
good agreement with the (native) UGT1A1 protein levels in these
biological samples, suggesting that the LC-FD based assay for
sensing UGT1A1 is reliable and can be used for sensing the real
activities of this key enzyme in complex biological samples.3.5. UGT1A1 inhibition assays
The newly developed LC-FD based method was also applied in
screening and characterization of UGT1A1 inhibitors, which is very
useful for assessing and preventing potential risks of drug/herb-
drug interactions. In this study, we used the leukemia drug niloti-
nib as a known UGT1A1 inhibitor to test the inhibitory effects of
nilotinib on UGT1A1 mediated NHPN-O-glucuronidation in re-
combinant hUGT1A1, pooled HLM and HeLa-UGT1A1 cells. As
shown in Fig. 5, UGT1A1-mediated NHPN-O-glucuronidation in all
the tested enzyme sources could be strongly inhibited by nilotinib
in a dose-dependent manner. The IC50 values for nilotinib, however,
varied between the enzyme sources and they were 29.2 nM,
53.1 nM and 1494.0 nM, for recombinant UGT1A1, HLM and HeLa-
UGT1A1 cells, respectively (Table S3). The data showed that the
inhibition potency of nilotinib against UGT1A1 in living cells is
much weaker than in recombinant UGT1A1 and in the isolated
microsomal fraction of liver cells. Notably, the much weaker inhi-
bition of UGT1A1 by nilotinib in intact cells, as revealed by our
results (Table S3) was in good agreement with the approval of
nilotinib as drug and that hyperbilirubinemia was not its main side
effect. In addition, the new inhibition results were consistent with
those in the previous reports regarding UGT1A1 inhibition [19], and
also suggested that the newly developed LC-FD based assay is
suitable for characterization and screening UGT1A1 inhibitors in
different enzyme sources.3.6. UGT1A1 induction assays
The new LC-FD based assay was subsequently used to evaluate
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In this study, Caco-2 cells were used as model cells, while real-time
PCR and NHPN-based biochemical methods were used to measure
themRNA level and catalytic activities of UGT1A1, respectively [20].
As shown in Fig. 6, both the mRNA level and O-lucuronidation ac-
tivities of UGT1A1 were significantly enhanced by the presence of
chrysin in the incubation medium in a dose-dependent manner.
Furthermore, the increase in UGT1A1 activities (determined by the
new LC-FD assay with NHPN as the substrate) matched quite well
the relative abundance of UGT1A1 mRNA levels (detected by real-
time PCR). The only slight difference was the relatively high activ-
ities seen already at the control sample, which could be attributed
to the fact that UGT1A1 had already been expressed before the start
of the experiment. Taking all the results in Fig. 6 into account, the
results clearly demonstrated that the newly developed UGT1A1
activities assay provided a practical assay for screening and char-
acterization UGT1A1 inducers via monitoring the formation of
NHPNG in living cells.
4. Conclusion
In summary, a reliable and easy-to-use LC-FD based assay has
been developed and validated for ultra-sensitive UGT1A1 activities
assays in various biological systems, using NHPN-O-glucur-
onidation as the probe reaction. The newly developed LC-FD based
assay shows several important advantages over previously re-
ported UGT1A1 activities assays, including high selectivity and
sensitivity, reliable and ease of use, as well as strong anti-
interference ability. The LOQ of the LC-FD based assay is much
lower than that of previously reported UGT1A1 activities assays,
making this assay more suitable for sensing UGT1A1 activities in
real samples. Furthermore, the new assay system has been suc-
cessfully applied to quantify UGT1A1 activities in human tissue
preparations and even to screening the regulatory effects of small
molecules on UGT1A1 in living cells. Collectively, this study pro-
vides a reliable and easy-to-use method for sensing UGT1A1 ac-
tivities in biological systems, which will be very useful for exploring
the relevance of this conjugative enzyme to human diseases, as
well as for rapid screening and discovery of effective modulators,
both inhibitors and inducers of this key enzyme.
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